

# SERUM AND SYNOVIAL FLUID LEVELS OF MATRIX METALLOPROTEINASE-3 AS A BIOMARKER OF JOINT DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS

#### Thesis

Submitted in partial fulfillment of MD Degree in Internal Medicine

By

Salma Ashraf Khalil

M.B.B.Ch., MSc.

Supervised by

#### Prof. Dr. Eman Ahmed Hafez

Professor of Internal Medicine and Rheumatology Faculty of Medicine - Ain Shams University

#### Prof. Dr. Samah Abdel Rahman El Bakry

Professor of Internal Medicine and Rheumatology Faculty of Medicine - Ain Shams University

#### Dr. Maryam Ahmed Abdel-Rahman

Assistant Professor of Internal Medicine and Rheumatology Faculty of Medicine - Ain Shams University

#### Dr. Hossam Moussa Sakr

Assistant Professor of Radiology Faculty of Medicine - Ain Shams University

#### Dr. Naglaa Afifi Mohamed

Lecturer of Internal Medicine and Rheumatology
Faculty of Medicine - Ain shams University
Faculty of Medicine
Ain Shams University
2018

# Acknowledgement

First and foremost, I feel always thankful to **Allah**, the most gracious and the most merciful.

I can hardly find words to express my gratitude to **Prof. Dr. Eman Ahmed Hafez, Professor of Internal Medicine and Rheumatology,** for her supervision and continuous help since the period of participants recruitment and sampling till the end of the study.

I would like also to express my sincere appreciation to **Prof. Dr.**Samah Abdel Rahman El Bakry, Professor of Internal Medicine and Rheumatology, for her guidance and valuable effort through each and every step of the work.

I am very thankful to **Dr. Maryam Ahmed Abdel-Rahman, Assistant Professor of Internal Medicine and Rheumatology,** for her generous advice and valuable hints during writing the thesis.

I am very grateful to **Dr. Hossam Moussa Sakr, Assistant Professor of Radiology,** for his outstanding effort performing the Ultrasound studies and revising the imaging part in the study.

I am thankful to my supervisor **Dr. Naglaa Afifi Mohamed, Lecturer of Internal Medicine and Rheumatology,** for her constant help and support during writing and revising the whole text.

A lot of thanks go to the patients and volunteers who participated in this work, for the sake of better health to the Egyptian community.

I dedicate this work to **my family** for their continuous encouragement and patience.

Salma Ashraf Khalil

## **List of Contents**

	Title	Page
•	List of Abbreviations	I
•	List of Tables	III
•	List of Figures	III
•	Introduction	1
•	Aim of the Study	4
•	Review of Literature	5
•	Subjects and Methods	74
•	Results	83
•	Discussion	110
•	Conclusion	120
•	Recommendations	121
•	Summary	122
•	References	126
•	Arabic Summary	

**AAOS** American Academy of Orthopaedic

Surgeons

**ACI** Autologous Chondrocyte Implantation

**ACR** American College of Rheumatology

**ACS** Acute Coronary Syndrome

**AD** Alzheimer Disease

**ADLs** Activities of Daily Living

**ALT** Alanine Aminotransferase

**Anti-CCP** Anti-Cyclic Citrullinated Peptides

**AS** Ankylosing Spondylitis

**AST** Aspartate Aminotransferase

**AUC** Area Under Curve

**AZA** Azathioprine

**bDMARD** Biological Disease Modifying

Antirheumatic Drugs

**BMP-7** Bone Morphogenetic Protein-7

**BUN** Blood Urea Nitrogen

**CBC** Complete Blood Count

**CDAI** Clinical Disease Activity Index

**CNS** Central Nervous System

COX-2.....Cyclo-Oxygenase-2

CRC Colorectal cancerCRP C-reactive protein

**csDMARDS** Conventional Synthetic Disease

Modifying Antirheumatic Drugs

**CSF** Cerebrospinal Fluid

CTLA-4 Cytotoxic T-Lymphocyte–associated

Antigen 4

**DAS** Disease Activity Score

**DAS28** Disease Activitty Score Based on 28

Joint Count

**DMARDs** Disease Modifying Antirheumatic Drugs

**ECM** Extracellular Matrix

**EGF** Epidermal Growth Factor

**ELISA** Enzyme Linked Immuno Sorbent Assay

**EMMPRIN** Extracellular Matrix Metalloproteinase

Inducer

**ER** Erosions

**ESR** Erythrocyte Sedimentation Rate

**EULAR** European League against Rheumatism

**FGF** Fibroblast Growth Factor

**HSA** Human Serum Albumin

**HCQ** Hydroxycholorquine

**HRCT** High Resolution Computed Tomography

**IFN** Interferon

**IGF** Insulin like Growth Factor

IgG Immunoglobin G
IgM Immunoglobin M

IL Interleukin

**ILD** Interstitial Lung Disease

**IV** Intravenous

**JSN** Joint Space Narrowing

**K/L** Kellgren and Lawrence system

**Kda** Kilodalton

**LEF** Leflunomide

**LFT** Liver Function Test

MCP Metacarpophalangeal

MG Myasthenia gravis

MHZ Megahertz

MI Myocardial Infarction

**MMP-3** Matrix Metalloproteinase-3

**MMPIs** Matrix metalloproteinases Inhibitors

**MMPs** Matrix Metalloproteinases

**MMSE** Mini Mental State Examination

MRI Magnetic Resonance Imaging

**MS** Multiple sclerosis

**MTP** Metatarsophalangeal

MTX Methotrexate

NO Nitric Oxide

**NPV** Negative Predictive Value

**NSAID** Non-steroidal Anti-inflammatory Drugs

**OA** Osteoarthritis

**OARSI** Osteoarthritis Research Society

International

**OD** Optical Density

**OMERACT** Outcome Measures in Rheumatoid

Arthritis Clinical Trials

**PAS** Pulomnry Artery Systolic Pressure

**PDGF** Platelet Derived Growth Factor

**PGA** Patient Global Assessment of general

health

PIP Proximal Interphalangeal

**PNGD** Palisaded Neutrophilic Granulomatous

**Dermatitis** 

**PPV** Positive Predictive Value

**PRP** Platelet Rich Plasma

**P-Value** Propability Value

**PVR** Pulmonary Vascular Resistance

**RA** Rheumatoid Arthritis

**RANKL** Receptor Activator of Nuclear factor

kappa-B Ligand

**RF** Rheumatoid Factor

**rhBMP-7** Recombinant Human Bone

morphogenetic Protein-7

**rhFGF** Recombinant Human Fibroblast

Growth Factor

**RND** Rheumatoid Neutrophilic Dermatosis

**ROC curve** Receiver Operating Characteristic

Curve

**RV** Rheumatoid Vasculitis

**SC** Subcutaneous

**SDAI** Simplified Disease Activity Index

**SENS** Simple Erosion Narrowing Score

**SF** Synovial fluid

**SLE** Systemic Lupus Erythematosus

**SNP** Single Nucleotide Polymorphism

**SNRIs** Serotonin Norepinephrine Reuptake

**Inhibitors** 

**SPSS** Statistical Program for Social Science

sSS Secondary Sjögren's Syndrome

**SvdH** Sharp/van der Heijde Score

**TBS** Tris Buffered Saline

**TGF-beta** Transforming Growth Factor Beta

**TIMPS** Tissue Inhibitors of Metallo-

proteinases

**TMB** Tetra-Methyl Bnezidine

**TMJ** Temporomandibular Joint

**TNF** Tumor Necrosis Factor

**tsDMARD** Targeted Synthetic Disease

Modifying Antirheumatic Drugs

**US** Ultrasound

**US28 score** The 28 Joint Ultrasound Score

**US7 score** The 7 Joint Ultrasound Score

**VAS** Visual Analogue Scale of pain

**VEGF** Vascular Endothelial Growth Factor

**WBC** White Blood Cell

**β-NGF** Beta Nerve Growth Factor

Table No.	Title Page	
Table (1):	The 2010 ACR/ EULAR classification criteria for rheumatoid arthritis 18	
Table (2):	RA clinical disease activity indices 20	
Table (3):	Conventional synthetic DMARDs used for rheumatoid arthritis treatment	
Table (4):	Biological DMARDs for rheumatoid arthritis treatment	
Table (5):	Stages of pain in Osteoarthritis 40	
Table (6):	ACR Clinical Classification Criteria for Osteoarthritis of the knee using clinical, laboratory and radiological investigations	
Table (7):	Current recommended OA drugs by AAOS and OARSI	
Table (8):	ACR recommendations for management of hand osteoarthritis 46	
Table (9):	ACR recommendations for management of knee osteoarthritis 47	
Table (10):	ACR recommendations for management of hip osteoarthritis	
Table (11):	New OA drugs and emerging therapeutics investigated in clinical studies	

Table No.	Title	Page
Table (12):	The family of metalloproteinases	
Table (13):	DAS28-ESR score Interpre	etation 75
Table (14):	OMERACT semi-quantitative scale for joint assessment	
Table (15):	Kellgren and Lawrence system (K/L) for classification of osteoarthritis of knee	
Table (16):	Comparison between the groups regarding age and	
Table (17):	Descriptive laboratory d studied parameters in patients of RA group	the 40
Table (18):	Descriptive clinical data of the 40 patients of RA group	
Table (19):	Assessment of disease activity in the 40 patients of RA group according to DAS-ESR	
Table (20):	Ultrasound assessment MCP, and PIP joints in regarding OMERACT spresence/absence of erosi	RA group, score and
Table (21):	Descriptive characteristic RA patients in whom syn 3 levels were assessed	ovial MMP-

Table No.	Title Page
Table (22):	Assessment of knee joints in 20 patients of OA group by Kellgren and Lawrence score (K/L)
Table (23):	Serum and synovial levels of MMP-3 in the 5 OA patients whose synovial MMP-3 levels were assessed
Table (24):	Levels of serum MMP-3 in the three studied groups
Table (25):	Comparison between RA group, OA group, and healthy control group regarding serum MMP3 level (ng/ml) by ANOVA test
Table (26):	Comparison between RA group and control groups regarding serum MMP3 level (ng/ml)
Table (27):	Comparison between RA group and OA group regarding synovial MMP3 level (ug/ml)
Table (28):	Comparison between grades of RA disease activity regarding serum level of MMP-3 (ng/ml) using ANOVA test
Table (29):	Comparison between grades of RA disease activity regarding Ultrasound findings

Table No.	Title	Page
Table (30):	Correlation between se levels (ng/ml) in RA different disease parame Pearson Correlation Coef	group and eters, using
Table (31):	Correlation between se levels (ng/ml) in RA group score and Ultrasound fin Pearson Correlation Coeffi	o, with SENS dings, using
Table (32):	Correlation between perosions on US and ser levels in RA group using	rum MMP-3
Table (33):	Correlation between synovial MMP3 levels in but not OA group, using Correlation Coefficient	n RA group ing Pearson
Table (34):	Correlation between se level (ng/ml) and K/L so joints in OA group, us Correlation Coefficient in	core of knee ing Pearson
Table (35):	Diagnostic Performance MMP3 level (ng/ml) to RA from OA	discriminate
Table (36):	Diagnostic Performance MMP3 level (ng/ml) to OA from healthy control a	discriminate
Table (37):	Diagnostic Performance MMP3 level (ng/ml) to RA from healthy control g	discriminate

# **List of Figures**

Figure No.	Title	Page
Figure (1):	Algorithm based on the 2016 recommendations on rhe arthritis management	eumatoid
Figure (2):	Simplified presentation pathophysiology of OA	
Figure (3):	Schematic presentation of structure	
Figure (4):	ORIGENE system for modern MMP-3 in human biological f	
Figure (5):	Gender distribution of the groups	
Figure (6):	Assessment of disease activing group according to DAS-ESR	•
Figure (7):	Ultrasound assessment of MCP, and PIP joints of RA g OMERACT score and j /absence of erosions	roup, by presence
Figure (8):	Mild synovial hypertrophy, minimal effusion, and erosion in the right 5 <sup>th</sup> MCP joint	
Figure (9):	Mild synovial hypertroph minimal effusion with mild signals in the right 3rd MCP	vascular
Figure (10):	Moderate synovial hypertroperosion in the right 2nd PIP j	_

# **List of Figures**

Figure No.	Title	Page
Figure (11):	Erosion of the right ulna process	
Figure (12):	Moderate vascular signals of wrist joint	
Figure (13):	Assessment of knee joint group by Kellgren and score (K/L)	Lawrence
Figure (14):	Comparison between RA group, and healthy contraregarding serum MMP3 level	ol group
Figure (15):	Comparison between RA group regarding synoval 3level (ug/ml)	ial MMP-
Figure (16):	Comparison between graded disease activity regarding level of MMP-3	g serum
Figure (17):	Comparison between grade disease activity regarding Ulfindings	trasound
Figure (18):	Positive correlation between MMP3 and RF among RA gro	
Figure (19):	Positive correlation between MMP3 and Anti-CCP and group	nong RA
Figure (20):	Positive correlation between MMP3 and CRP among RA g	

# **List of Figures**

Figurer No	. Title	Page
Figure (21):	Positive correlation betw MMP3 and DAS-ESR group	among RA
Figure (22):	Positive correlation between MMP3 levels and grades on B Mode Ultrasound group	of synovitis among RA
Figure (23):	Positive correlation betw MMP3 and vascular sign Doppler Ultrasound among	nals seen on
Figure (24):	Positive correlation between and synovial levels of M group	MMP3 in RA
Figure (25):	Significant positive between serum MMP3 ar in group OA	nd K/L score
Figure (26):	Receiver-operating control (ROC) curve to discriming OA	ate RA from
Figure (27):	Receiver - operating control (ROC) curve to discriming the healthy control group	ate OA from
Figure (28):	Receiver-operating characteristic curve to discriminate RA control group	from healthy